

Chapter 2

Symptomatology and Clinical Features of Parkinson's Disease

Abdelaati El Khiat

Faculty of Medicine and Pharmacy, Higher Institute of Nursing Professions and Health, Morocco

Bilal El-Mansoury

Faculty of Sciences, Chouaib Doukkali University, Morocco

Driss Ait Ali

Independent Researcher, Morocco

Mohamed El Koutbi

Higher Institute of Nursing Professions and Health Techniques, Ouarzazate, Morocco

Kamal Kaoutar

Higher Institute of Nursing Professions and Health Techniques, Ouarzazate, Morocco

Youssef Ait Hamdan

 <https://orcid.org/0009-0005-8616-8852>

Higher Normal School, Morocco

Brahim El Houate

Higher Institute of Nursing Professions and Health Techniques, Ouarzazate, Morocco

Lahcen Tamegart

Independent Researcher, Morocco

Kamal Smimih

Faculty of Sciences and Techniques, Sultan Moulay Slimane University, Morocco

Adnane Hakam

Higher Institute of Nursing Professions and Health Techniques, Ouarzazate, Morocco

Najib Kissani

Independent Researcher, Morocco

Halima Gamrani

Independent Researcher, Morocco

ABSTRACT

Parkinson's disease (PD) is a progressive neurodegenerative disease representing the most common movement disorder worldwide. It is characterized clinically by its cardinal motor features: bradykinesia, rigidity, postural instability, and resting tremor. The clinical diagnosis of PD is mainly based on the presence of these motor symptoms which differentiate it from the other forms of parkinsonism. However, recently other symptoms known as non-motor symptoms (NMS) are gaining attention because of their

DOI: 10.4018/978-1-6684-5156-4.ch002

Symptomatology and Clinical Features of Parkinson's Disease

negative outcome on PD patients, and they are now included in the clinical diagnosis of the disease. Current lines treatments are generally based on DA replacement and are associated with significant alleviation of motor symptoms and some NMS. However, such treatments have not been shown to decrease or halt the disease progression. Moreover, as the disease progresses, these symptomatic treatments can worsen the disease diagnosis and management.

INTRODUCTION

Parkinson's disease (PD) is the second most common neurodegenerative disease and the commonest movement disorder worldwide. Clinically, PD is characterised by its cardinal motor symptoms which are Akinesia/bradykinesia, muscular rigidity, postural instability and resting tremor. It is highly established that these motor symptoms are caused by the degeneration of the dopamine (DA) producing neurons of the substantia nigra pars compacta (SNpc) of the midbrain leading to the nigrostriatal pathway dysregulation (Surmeier, 2018; Desai *et al.*, 2019 ; Gelders *et al.*, 2018). It is believed that during the onset of these cardinal motor symptoms, around 80% of dopaminergic neurons are already degenerated (Chung *et al.*, 2001). The current standard diagnosis of PD is clinical and the disease is usually diagnosed by the first motor symptoms.

The progression of symptoms in PD is highly variable among patients (Poewe, 2006). Indeed, one of the main issues in PD diagnosis is that every patient is different regarding the symptoms, severity, and progression; hence, it is even sometimes said that each patient has his or her own version of PD (Sveinbjornsdottir, 2016b). However, the presence of PD cardinal motor features is essential in order to differentiate PD from related parkinsonian disorders. Another important thing that can help to distinguish PD from the other parkinsonian syndrome is that most motor symptoms of PD are responsive to dopaminergic therapy and the main confirmation of PD identification is the positive response to dopaminergic therapy (D'costa *et al.*, 1995; Váradi, 2020).

Although in recent decades there have been large advances in symptomatic therapy of PD, therapies that will halt or slow the progression of the disease remain challenging (Poewe and Mahlknecht, 2009). With the disease progression, other motors and non motor symptoms (NMS) appear either as a result of the disease course or as complications of these pharmacologic testaments which eventually worsen both PD diagnosis and management. The NMS of PD includes sleep disorders, neuropsychiatric dysfunction, sensory symptoms, cognitive impairment, and dementia among others are also associated with poor quality of life (Schapira *et al.*, 2017; Ja *et al.*, 2012; Ziemssen and Reichmann, 2007). Additionally, most if not all PD symptoms are progressive, and their management is of great importance. In this chapter, the critical features of PD and their utilization in the clinical diagnostics are discussed.

PD Symptoms: A General Overview

PD is a multi-system, progressive neurodegenerative illness that primarily affects patients in their later years of life. In industrialised countries, the prevalence of PD is estimated at 0.3% of the total population and at roughly 1% in those over 60 (Lau, 2006). For both men and women, the prevalence rises

9 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

www.igi-global.com/chapter/symptomatology-and-clinical-features-of-parkinsons-disease/327962

Related Content

Dealing With Noise and Partial Volume Effects in Alzheimer Disease Brain Tissue Classification by a Fuzzy-Possibilistic Modeling Based on Fuzzy-Genetic Initialization

Lilia Lazliand Mounir Boukadoum (2021). *Research Anthology on Diagnosing and Treating Neurocognitive Disorders* (pp. 267-294).

www.irma-international.org/chapter/dealing-with-noise-and-partial-volume-effects-in-alzheimer-disease-brain-tissue-classification-by-a-fuzzy-possibilistic-modeling-based-on-fuzzy-genetic-initialization/261638

Machine Learning-Based Application for Long-Term Electrocardiogram Analysis

Jonathan Araujo Queiroz, Juliana M. Silva, Yonara Costa Magalhães, Will Ribamar Mendes Almeida, Bárbara Barbosa Correia, José Ricardo Santo de Lima, Edilson Carlos Silva Lima, Marcos Jose Dos Passos Saand Allan Kardec Barros Filho (2024). *Advances in Neuroscience, Neuropsychiatry, and Neurology* (pp. 51-64).

www.irma-international.org/chapter/machine-learning-based-application-for-long-term-electrocardiogram-analysis/342883

Building Resilient Organizations: Effect on Workforce Well-Being by Mediation of Labor Productivity in Gedeo Zone, Ethiopia

Shashi Kant, Dawit Jabo, Zinabu Wolde, Zerihun Kinde Alemuand Rakesh Kumar Gautam (2026). *Impact of Neuroplasticity on Organizational Effectiveness and Labor Productivity* (pp. 321-348).

www.irma-international.org/chapter/building-resilient-organizations/395481

Chitosan and Its Derivatives as Potential Neuro-Protective Agents for the Treatment of Parkinson's Disease

Youssef Ait Hamdan, Samia Elouali, Abdelali Ben Maloui, Bilal El-Mansoury, Hassane Oudadesseand Mohammed Rhazi (2023). *Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease* (pp. 253-274).

www.irma-international.org/chapter/chitosan-and-its-derivatives-as-potential-neuro-protective-agents-for-the-treatment-of-parkinsons-disease/327979

The Relevance of the Early Childhood Executive Functions With Preliteracy Learning: An Early Intervention Training Software in High Ability Preschoolers

Eleni Rachanioti, Anastasia Alevriadou, Tharrenos Bratitsisand Eleni Laskaraki (2022). *Handbook of Research on Neurocognitive Development of Executive Functions and Implications for Intervention* (pp. 340-364).

www.irma-international.org/chapter/the-relevance-of-the-early-childhood-executive-functions-with-preliteracy-learning/300950